Stem Cell Bioprocessing and Manufacturing
The next healthcare revolution will apply regenerative medicines using human cells and tissues. The aim of the regenerative medicine approach is to create biological therapies or substitutes in vitro for the replacement or restoration of tissue function in vivo lost through failure or disease. Howev...
| Format: | eBook |
|---|---|
| Language: | English |
| Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2020
|
| Subjects: | |
| Online Access: | Open Access: DOAB: description of the publication Open Access: DOAB, download the publication |
| LEADER | 05254namaa2201261uu 4500 | ||
|---|---|---|---|
| 001 | doab68946 | ||
| 003 | oapen | ||
| 005 | 20210501 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 210501s2020 xx |||||o ||| 0|eng d | ||
| 020 | |a 9783039430383 | ||
| 020 | |a 9783039430390 | ||
| 020 | |a books978-3-03943-039-0 | ||
| 024 | 7 | |a 10.3390/books978-3-03943-039-0 |2 doi | |
| 040 | |a oapen |c oapen | ||
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 720 | 1 | |a Cabral, Joaquim M. S. |4 edt | |
| 720 | 1 | |a Cabral, Joaquim M. S. |4 oth | |
| 720 | 1 | |a Diogo, Maria Margarida |4 edt | |
| 720 | 1 | |a Diogo, Maria Margarida |4 oth | |
| 720 | 1 | |a Lobato da Silva, Cláudia |4 edt | |
| 720 | 1 | |a Lobato da Silva, Cláudia |4 oth | |
| 245 | 0 | 0 | |a Stem Cell Bioprocessing and Manufacturing |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2020 | ||
| 300 | |a 1 online resource (170 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |f Unrestricted online access |2 star | |
| 520 | |a The next healthcare revolution will apply regenerative medicines using human cells and tissues. The aim of the regenerative medicine approach is to create biological therapies or substitutes in vitro for the replacement or restoration of tissue function in vivo lost through failure or disease. However, whilst science has revealed the potential, and early products have shown the power of such therapies, there is an immediate and long-term need for expertise with the necessary skills to face the engineering and life science challenges before the predicted benefits in human healthcare can be realized. Specifically, there is a need for the development of bioprocess technology for the successful transfer of laboratory-based practice of stem cell and tissue culture to the clinic as therapeutics through the application of engineering principles and practices. This Special Issue of Bioengineering on Stem Cell Bioprocessing and Manufacturing addresses the central role in defining the engineering sciences of cell-based therapies, by bringing together contributions from worldwide experts on stem cell biology and engineering, bioreactor design and bioprocess development, scale-up, and manufacturing of stem cell-based therapies. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |u https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a adipose stem cells | ||
| 653 | |a adipose-derived stem cell | ||
| 653 | |a advanced therapy medicinal products | ||
| 653 | |a allogeneic cell therapy | ||
| 653 | |a arthroscopy | ||
| 653 | |a arthrotomy | ||
| 653 | |a autologous therapy | ||
| 653 | |a axonal regeneration | ||
| 653 | |a bio-process | ||
| 653 | |a bioprocess | ||
| 653 | |a bioreactor | ||
| 653 | |a blood platelets | ||
| 653 | |a cell aggregate | ||
| 653 | |a cell culture techniques | ||
| 653 | |a cell growth | ||
| 653 | |a cell seeding | ||
| 653 | |a cell therapies | ||
| 653 | |a computational fluid dynamics | ||
| 653 | |a differentiation | ||
| 653 | |a disease modeling | ||
| 653 | |a drug screening | ||
| 653 | |a electrospinning | ||
| 653 | |a embryonic stem cells | ||
| 653 | |a expansion | ||
| 653 | |a fibrin nerve conduits | ||
| 653 | |a growth factors | ||
| 653 | |a hepatic cell lineages | ||
| 653 | |a hepatocyte differentiation | ||
| 653 | |a high voltage | ||
| 653 | |a hMSCs | ||
| 653 | |a homogeneous hydrodynamic environment | ||
| 653 | |a human adipose stem cells (hASCs) | ||
| 653 | |a human embryonic stem cell | ||
| 653 | |a human pluripotent stem cells | ||
| 653 | |a hydrogels | ||
| 653 | |a induced pluripotent stem cell | ||
| 653 | |a infrapatellar fat pad | ||
| 653 | |a kinetic growth modeling | ||
| 653 | |a knee | ||
| 653 | |a lactate | ||
| 653 | |a live-cell electrospinning | ||
| 653 | |a liver organoids | ||
| 653 | |a mesenchymal stromal cells | ||
| 653 | |a microcarrier | ||
| 653 | |a model predictive control | ||
| 653 | |a n/a | ||
| 653 | |a neural regeneration | ||
| 653 | |a neurotrophic factors | ||
| 653 | |a non-parenchymal liver cells | ||
| 653 | |a olfactory ensheathing cells | ||
| 653 | |a peripheral nerve injuries | ||
| 653 | |a progenitor cells | ||
| 653 | |a scalable manufacturing | ||
| 653 | |a scale up | ||
| 653 | |a Schwann cells | ||
| 653 | |a segregated and unstructured growth model | ||
| 653 | |a serum- and xeno-free conditions | ||
| 653 | |a shear stress | ||
| 653 | |a single-use bioreactor | ||
| 653 | |a spinal cord injury | ||
| 653 | |a stem cell | ||
| 653 | |a stem cells delivery | ||
| 653 | |a stromal vascular fraction | ||
| 653 | |a tissue engineering | ||
| 653 | |a turbulent energy dissipation rates | ||
| 653 | |a U-shaped vessel | ||
| 653 | |a UrSuppe stem cell culture medium | ||
| 653 | |a Vertical-Wheel | ||
| 653 | |a viability | ||
| 793 | 0 | |a DOAB Library. | |
| 856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/68946 |7 0 |z Open Access: DOAB: description of the publication |
| 856 | 4 | 0 | |u https://mdpi.com/books/pdfview/book/2713 |7 0 |z Open Access: DOAB, download the publication |